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Counterfeit and substandard medicines are recognized as one of serious threats to public 
health. The product quality of antibacterial medicine will compromise patients’ recovery 
and increase the chance of antibacterial resistance. The review aims to provide a summary 
of low quality levofloxacin issues and the risk factors as well as suggesting the aspects 
of product quality that need to be regulated strictly. Quality of the active ingredient, 
levofloxacin, has an important role to contribute to successful therapy. The poor quality of 
raw material, directly and indirectly, causes treatment failure as the presence of insufficient 
dose, mislabeled content, and poor dissolution characteristics can lead to lower 
bioavailability. Identifying and reporting these factors can potentially help in improving 
the quality of drug marketed in various developing countries and may also reduce the 
incidences of treatment failure. Dissolution test is used for testing the dissolution profiles 
and the rate of drug release from solid formulation such as oral formulations, thus providing 
information regarding the in vivo performance of a formulation and its bioequivalence. On 
the other hand, quality-testing procedures are used for comparing the quality of products.
Keywords: counterfeit, post marketing surveillance, regulatory requirement, fluroquinolone resistance, quality 
medicine
INTRODUCTION
Nowadays, treatment failure of infectious diseases is one of the major healthcare issues especially 
in developing countries (Lee et al., 2015). Respiratory tract infection (RTI) is one of the main 
microbial infections in developing countries that causes about 4–5 million deaths per year 
among children (Liu et al., 2014). For instance, pneumonia is an inflammation of air sacs in 
lungs and one of common RTI that may cause hospitalization and mortality (Lee et al., 2015; 
Crispian, 2016). Although the emergence of antibiotic therapy and vaccines in the twentieth 
century increased the survival rate among these patients, however, it was still reported that 
pneumonia caused a high incidence of death rate among geriatrics and children especially in 
the developing countries (Basnet et al., 2015). There are resistance cases reported on first-line 
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antibiotics such as penicillin and macrolides for the treatment 
of pneumonia. Quinolone class is considered as one of the 
empirical treatments of the infection (Endimiani et al., 2005). 
However, the rising of quinolone resistance cases is alarming 
in North and South American countries in the year 2000 
(Kays et al., 2002). Haemophilus influenzae is one of common 
organisms which can cause RTI, and there are few studies 
reported the quinolone-resistant of H. influenzae (Bastida et 
al., 2003). There are few studies suggesting that poor quality 
and substandard drugs are a major contributor to antibiotic 
resistance in RTIs in developing countries (Conway et al., 2013; 
Currie et al., 2014; Basnet et al., 2015). This draws the attention 
of regulatory authority to look into the aspect of poor quality 
medicines which were reported in many developing countries. 
It is reported that a significant percentage of generic drugs 
fails to meet the innovator specifications in Latin America 
(Nightingale, 2005).
Drug quality has a key role to deliver successful treatments. 
It is important to achieve the required minimum inhibitory 
concentration (MIC) in order to cure an infection (Miller 
et  al., 2005). High quality antibiotics are essential in treatment 
of serious common RTIs while poor quality antibiotic therapy 
may increase morbidity and mortality rates (Khasawneh et al., 
2014). Hence, the aim of this review is to summarize low quality 
levofloxacin tablet issue and suggest aspects of product quality 
that need to be strengthen and regulated strictly.
LEVOFLOXACIN RESISTANCE
Previous studies conducted in South Korea, Canada, USA, 
and Spain show the correlation between fluoroquinolone 
administration and resistance (Kays et al., 2002). The resistance 
of microbes toward some fluoroquinolones products have 
been reported in the treatment of hospital acquired infections 
(Torloni et al., 2016). Kays et al. (2002) have claimed that 
levofloxacin susceptibility in pneumonia infection had 
reduced as utilization of levofloxacin prescription increased. 
Meanwhile, Davidson et  al. (2002) reported treatment failure 
in Streptococcus pneumoniae in three different cases after 
fluoroquinolone administration. Fluoroquinolone resistance 
is reported in some developing countries such as China and 
Thailand with 3% non-susceptibility to levofloxacin while the 
fluoroquinolone resistance against S. pneumonia is below 1% in 
the United States from 1987 to 1998 (Sahm et al., 2000; Hu et al., 
2011). Although, the results in the United States may be related 
to different prescribing behaviors or fundamental characteristics 
of the selected pathogens, but S. pneumonia is still capable of 
resistance development in fluoroquinolone therapy (Sahm et 
al., 2000; Davidson et al., 2002). Seok et al. (2018) have stated 
evidence for non-susceptibility to levofloxacin due to prior 
usage of antibiotics within 3 months, and it is recommended 
to restrict unnecessary fluoroquinolone prescriptions. Also, 
Ayukekbong et al. (2017) have presented multiple factors 
contributing to the problem of antimicrobial resistance due to 
unnecessary antibiotic prescriptions, especially in developing 
countries. Available evidence suggests that non-susceptibility to 
levofloxacin is an ongoing problem.
POOR QUALITY DRUG PRODUCTS
Poor quality drug product is a major global healthcare issues 
(Sarpong and Miller, 2014). There are studies suggesting 
that antibacterial drugs mainly antimalarial, antiviral, and 
antibiotics are among the poor quality drug products reported 
in developing countries (Nsimba, 2008; Melo et al., 2014). 
Poor quality drug product is defined as drug product which 
the drug content does not follow the provided standards 
such as chemical stability, bioavailability, and purity in drugs 
(Almuzaini et al., 2013). Poor quality drug product can be sub-
classified into substandard drugs product and counterfeit drug 
product (Newton et al., 2010). Substandard drug products are 
medicines produced by an authorized manufacturer which do 
not follow designated standard quality standings. On the other 
hand, counterfeit medicines are defined as “deliberately and 
fraudulently mislabeled with respect to identity and/or source” 
whether with the right or falsified ingredients or with the forged 
labeling. Substandard/counterfeit medicines are not usually 
bioequivalent due to differences in bioavailability as a result of 
pharmacokinetics (Johansson et al., 2010).
Moreover, some poor quality drugs do not have good in vivo 
dissolution in the gastrointestinal tract leading to incomplete 
absorption; hence, therapeutic levels in blood cannot be 
achieved (Johansson et al., 2010). The MIC is not achieved 
when the drug plasma concentration is below expectation 
which leads to therapy failure and antibiotic resistance 
(Almuzaini et al., 2013).
Table 1 shows the relevant studies which reported the 
substandard/counterfeit drugs. These studies claim that there are 
many substandard or counterfeit drugs available in developing 
counties (Nightingale, 2005; Hosseini et al., 2011; Bate et al., 
2013; Khurelbat et al., 2014; Lalani et al., 2015).
TABLE 1 | The percentage of substandard, counterfeit, and unregistered 
levofloxacin available in the market of different countries.
Regions Substandard/
counterfeit
(%)
Total 
samples
References
Africa
India
Middle income 
countries
16.6
10.1
3.9 
713 * (Bate et al., 2013)
Iran 9.1 7910 (Hosseini et al., 2011)
Mongolia 18 388 (Khurelbat et al., 2014)
Afghanistan 26 126 (Lalani et al., 2015)
13 countries 
including Asia and 
Latin America
20 40 (Nightingale, 2005)
*The studies were conducted in different countries such as Angola, Brazil, China, 
Democratic Republic of Congo, Egypt, Ethiopia, Ghana, India, Kenya, Nigeria, Russia, 
Rwanda, Thailand, Turkey, Uganda, and United Republics of Tanzania and Zambia.
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In addition, many studies have confirmed that substandard or 
counterfeit drugs caused side effects such as allergies because of 
impurity, toxicity, or a high percentage of the active agent (Tipke 
et al., 2008; Wang et al., 2015). Substandard drugs may lead to 
potential side effects and death as the higher or lower amount of 
drug than the labeled one is delivered (Boyd et al., 2009; Tamargo 
et al., 2015; Wang et al., 2015).
ASPECTS OF PRODUCT QUALITY
It is important that the generic pharmaceutical manufacturers 
ensure the production of quality products which help to reduce 
the therapy failure and antibiotic resistance. Several aspects of 
product quality is discussed in this review—namely, dissolution 
study and bioequivalence, quality control of product, quality 
control test and stability of drug product, post-marketing 
surveillance (PMS), effect of storage, and poor quality control 
during manufacturing.
DISSOLUTION STUDY AND 
BIOEQUIVALENCE
A generic drug is defined as a product which has the same 
active ingredients as the innovator medicine but with different 
inactive agents or excipients (Nitzki-George, 2004). Generic drug 
products are cheaper than the innovator drug products due to 
the initial saving of research and development expenses for new 
drugs, so they are highly preferred in the society especially by low 
income patients (Dunne et al., 2013).
One of the ways to show drug quality of generic product is 
through bioequivalence study. Bioequivalence study is required 
to ensure that the generic medicine product is equivalent with 
the innovator medicine product in terms of pharmacokinetics 
requirement as maximal serum concentration and area under the 
curve (drug concentration against time) (Johansson et al., 2010). 
Hence, FDA uses a bioequivalent approach to assess generic 
drugs (Paveliu et al., 2011). A bioequivalent is considered if the 
two drugs in comparison have less than 20% difference in the 
pharmacokinetics parameters (Paveliu et al., 2011). Thus, generic 
drug manufacturers are required to prove that rate and extent 
of drug absorption into the bloodstream is comparable to the 
amount from a brand name product (Davit et al., 2009).
Although, both generic and innovator drugs are susceptible 
to be falsified, but generic medications are easier to be 
manipulated (Gibson, 2005). In most cases, samples of generic 
drugs are as safe and effective as branded one, but still some 
problems may occur (Kesselheim et al., 2008). Treatment 
failures have been reported in different cases, such that in one 
case, symptoms were improved after replacing the prescribed 
generic levofloxacin with Tavanic (Innovator product) without 
the presence of any adverse effect (Gallelli et al., 2013). The 
issue was identified as the excipients of the generic product is 
different (Tamargo et al., 2015). Although the active content 
that helps to control may be the same, the filler material, color, 
or binder used may be different (Tamargo et al., 2015). The 
problem may occur when the active agent is not sufficient or the 
inactive content has impurity or contamination that can have 
a great impact on bioavailability, metabolism, and elimination 
(Tamargo et al., 2015).
QUALITY CONTROL AND STABILITY OF 
DRUG PRODUCT
Pharmaceutical industries need to adhere and comply with the 
good manufacturing practice (GMP) to guarantee the products 
safety, efficacy, and quality (Li et al., 2015). Nowadays, export 
or occasional drug use among the country of production is also 
subjected to compliance with GMP requirements and regulations 
by manufacturer (Abdellah et al., 2015). Compliance with the 
requirements and regulation of GMP is considered as an essential 
and vital aim for quality assurance and ultimately the profitability 
of the pharmaceutical industry (Tomic et al., 2010).
Analysis of raw materials, substances, and intermediate 
products are important tasks in pharmaceutical manufacturing 
and quality control. Pharmacopeia is used as a reference for 
chemical, physical, and microbiological tests (Kaul et al., 
2016). The manufacturers are responsible to not just produce 
a final product, but they are also obliged to look into the post-
production drug product stability issues (Lambert and Conway, 
2003; Wang et al., 2015; Kaul et al., 2016). U.S. Pharmacopeia 
(USP) is one of commonly available pharmacopeia to control 
quality of raw materials, components, packaging, and final 
products (Panchagnula et al., 2006; Kaul et al., 2016).
Innovator (brand name) and generic medicines use the 
same API, but they may contain diverse inactive agents while 
they still need to follow quality standards of innovator drug (Al 
Ameri et al., 2012). Quality control is essential for detecting the 
substandard drugs containing inactive substance, impurities, 
and toxic substances (Almuzaini et al., 2013; Fadeyi et al., 2015). 
Substandard drugs can be detected using the quality-testing 
protocols such as USP which is also defined by the World Health 
Organization and International Pharmacopeias (Kayumba et al., 
2004; Maezawa et al., 2013).
The drug product should contain an equal amount of active 
pharmaceutical ingredient (API) as stated in the product claim 
(Zaid et al., 2013). According to WHO’s definition, an API 
is a material or combination of materials that are used in the 
pharmaceutical products as an active compound with a direct 
effect in treatment (World Health Organization, 2011; World 
Health Organization, 2016). The compatibility between API and 
excipients is important to ensure stability of the API in the dosage 
form. A stable API will deliver the claimed effect within the shelf 
life of the product. A crucial role of excipient in drug formulation 
requires the regulatory approval to avoid toxic or poor quality 
medicines that may lead to treatment failure (Baldrick, 2000).
Effect of Storage Conditions on Drug 
Stability
Storage is one factor that may affect the quality of a drug 
(Kayumba et al., 2004). The storage under tropical conditions 
Product Quality of LevofloxacinIzadi et al.
4 August 2019 | Volume 10 | Article 881Frontiers in Pharmacology | www.frontiersin.org
was reported by Kayumba et al. (2004) as the main problem 
of the instability of some formulations of drugs collected in 
Tanzania, and it was suggested to drug regulatory authorities to 
develop a quality assurance system to control poor quality drugs. 
Another study by Nogueira et al. (2011) claims that storage has 
an essential role in the stability of the drug after production, and 
poor drug samples were found in poor drug storage conditions in 
75% relative humidity and 40°C.
Poor Quality Control During 
Manufacturing
Quality control framework based on established pharmacopeia 
techniques is essential to ensure product quality (Losada-
Urzáiz et al., 2015). Moreover, lack of quality control due 
to irresponsibility and corruption increase the percentage 
of supplying counterfeit drugs in the market which lead to 
serious public health issues (Zavras et al., 2016). One of the 
main reasons for quality problems in developing or low income 
countries is lack of PMS and regulation (Taylor et al., 2001). 
The financial issue may increase the percentage of treatment 
failure and resistance due to poor quality or counterfeit drugs 
in developing countries (Taylor et al., 2001; Nsimba, 2008). 
Nevertheless, the number of cases of substandard or poor 
quality drugs are significant in low income and developing 
countries which can be related to limited financial support in 
health care, PMS, and pharmaceutical manufacturing (Taylor et 
al., 2001; Tipke et al., 2008; Conway et al., 2013; Karunamoorthi, 
2014; Fadeyi et al., 2015).
Control Measures to Reduce Low Quality 
Drugs
Low quality medicine produced during pharmaceutical 
manufacturing can be detected using drug dissolution studies 
(Wang et al., 2015). The most effective way to reduce the low 
quality drugs in the market is strictly prohibiting entry of 
counterfeit drugs into the market (Losada-Urzáiz et al., 2015). 
The other way to ensure both innovator and generic drugs 
are following standards and regulations is clearly expressed 
to the manufacturers that the specific pharmacopoeial 
techniques need to be complied (Losada-Urzáiz et al., 2015). 
Bioequivalence study is a must to ensure that the generic 
product is equivalent with the innovator product.
CASE STUDY: LEVOFLOXACIN
Levofloxacin is a broad spectrum antibiotic which belongs to the 
third generation of quinolones group (Scoper, 2008). It prevents 
DNA replication in bacteria leading to bacterial cell death, and 
it is mainly used as a second-line therapy of lungs infection 
(Noreddin and Elkhatib, 2010). This drug is considered as an 
important antibiotic in case of microorganism that is resistant to 
other class of antibacterial agents such as beta-lactam antibiotics; 
hence, its quality is critical in effective treatment (Kayumba et al., 
2004; Endimiani et al., 2005).
Levofloxacin is chosen as the model drug for a common 
empirical treatment of pneumonia caused by Gram-negative 
bacteria such as H. influenza as well as Gram-positive bacteria 
such as S. pneumoniae (Kays et al., 2002).
Levofloxacin has high oral bioavailability with rapid 
bactericidal activity; hence, it is considered for the treatment 
of choice for severe pneumonia (Boyd et al., 2009; Maezawa 
et al., 2013). Although, levofloxacin is one of the most widely 
prescribed agents for the pneumonia treatment but the number 
of treatment failure incidences have been recently increased 
with levofloxacin therapy (Kays et al., 2002; Bastida et al., 2003; 
Endimiani et al., 2005; Boyd et al., 2009). The possible risk 
factors suggested for the treatment failure of levofloxacin are 
poor quality medicines and drug resistance (Davidson et  al., 
2002). Death in pneumonia due to levofloxacin treatment 
failure has been reported in North America as four patients in 
Canada and one patient in the USA in 2000–2001 (Davidson 
et al., 2002; Kays et al., 2002). Pneumonia can be caused by 
virus, bacteria, or fungi, and it is commonly categorized as 
community-acquired pneumonia (CAP) and hospital-acquired 
pneumonia (HAP) (Abrahamian et al., 2008). The CAP is 
caused by Streptococcus pneumoniae, Haemophilus influenzae, 
Chlamydia pneumoniae, and respiratory viruses (Abrahamian 
et al., 2008; Johansson et al., 2010). On the other hand, 
HAP occurs after 48 h of hospital admission by Escherichia 
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and 
Staphylococcus aureus, including methicillin-resistant S. 
aureus (MRSA) (Imran et al., 2016). The treatment is chosen 
on the basis of different categories and the causative organisms 
(Imran et al., 2016). The main treatment of pneumonia is 
antibiotics while sometimes the patients need to be admitted 
to the hospital to monitor their progression (Bradley et al., 
2014). In addition, approving a specific microbial etiology is 
important in empirical treatment of pneumonia to minimize 
the risk of exposed side effects and antibiotic resistance 
(Leekha et al., 2011). There are different types of antibiotics 
used for treatment of pneumonia especially in CAP which is 
the most common pneumonia and may cause serious infections 
globally (Abrahamian et al., 2008). Although, the particular 
antibiotic for management of CAP is given based on severity 
of infections or etiology (pathology) while combination of 
beta-lactam (amoxicillin) and macrolides (azithromycin) or 
antipneumococcal fluoroquinolone are the preferred empirical 
treatment (Mandell et al., 2007).
TABLE 2 | Features of treatment failure of pneumonia due to levofloxacin-
resistant in different countries.
Disease-causing 
bacteria
Reported country References
Haemophilus influenzae Spain (Bastida et al., 2003)
Staphylococcus aureus Pakistan (Rizvi et al., 2014)
Streptococcus 
pneumoniae
Canada (Davidson et al., 2002)
Italy (Endimiani et al., 2005)
USA (Kays et al., 2002)
Hong Kong (Ho et al., 2001)
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Therapeutic window is the range between the amount of the 
drug that gives the desired effect and the drug may be ineffective 
or toxic if the drug therapeutic index is below or above the 
range, respectively (Tamargo et al., 2015). Treatment failure 
may occur by various factors such as an inadequate antibiotic 
coverage and concentration, deficient diagnosis, or resistance 
(Sánchez García, 2009). Poor quality antibacterial may lead to 
drug resistance or severe side effects if the therapeutic window 
of levofloxacin is not achieved (Boyd et al., 2009; Tamargo et al., 
2015). Therefore, if the dose is lower than the standard window, 
the drug is not effective, and it may increase resistance; on the 
other hand, if above the MIC range, then it may cause toxicity 
and adverse reaction (Tamargo et al., 2015). Additionally, 
levofloxacin is a broad spectrum antibiotic which is susceptible 
to cause resistance of normal flora; hence, substandard drugs 
may increase the risk of resistance significantly (Kays et al., 
2002; Bastida et al., 2003).
Poor quality antibacterial product may lead to drug 
resistance, severe side effects, and death; hence, it has a critical 
role in the treatment and public health (Melo et al., 2014). There 
are many factors causing resistance, such as irrational and 
excessive use caused by wrong prescribing and poor quality of 
medicine (Melo et al., 2014). Table 2 shows the relevant studies 
reported levofloxacin resistance to H. influenza, S. pneumoniae, 
and S. aureus species in different pneumonia. Even though, the 
site of infections and treatments are different from each other, 
but it shows levofloxacin resistance have occurred (Ho et al., 
2001; Davidson et al., 2002; Kays et al., 2002; Bastida et al., 2003; 
Endimiani et al., 2005). Thus, it is evident that levofloxacin 
resistance is one of the main reasons behind treatment failure 
of pneumonia (Endimiani et al., 2005). Therefore, public 
awareness about low quality medicine can be created through 
the reported resistant susceptibility and quality of levofloxacin 
(Talan et al., 2016).
Dissolution Testing of Levofloxacin Tablets
Quality control tests used to identify substandard drugs and 
control the quality of drugs are colorimetric, dissolution, 
chromatography, and spectrometry procedures (Almuzaini 
et al., 2013; Maezawa et al., 2013). Dissolution test provides the 
data of in vitro performance of the drug and prediction for its 
bioequivalence (Anand et al., 2011). Hence, it is used to estimate 
the concentration of API and also drug quality (Anand et al., 
2011). The dissolution rate consists of drug release by dissolving 
of solid form in an API into the fluid to determine the stability 
and physical changes (Kayumba et al., 2004; Nogueira et al., 
2011). Drug dissolution test is an essential factor to identify 
the quality of drugs especially in oral administration as it 
provides the process of drug release from its solid formulation, 
and it can discriminate the substandard and low quality 
products (Lambert and Conway, 2003; Al Ameri et al., 2012; 
Khadka et al., 2014).
Dissolution test is required to be applied under in vitro 
conditions to compare the drug release of active ingredient 
from a solid form into solution and its bioavailability during a 
defined time (Frick et al., 1998). Previous studies on dissolution 
of levofloxacin have shown little variation in levofloxacin 
tablets tested in different countries. Table 3 shows the various 
dissolution studies of levofloxacin tablets conducted in 
various countries.
It is observed that certain generic brands in Japan, Taiwan, 
Pakistan, and India showed difference in dissolution profile 
when compared with the innovator product. There is only 
one study by Bano et al. (2011) comparing few generic brands 
of levofloxacin tablet does not show significant difference 
in dissolution profile. The result of this study shows that the 
different in vitro activity may have a direct effect on the in 
vivo activities and demonstrate the predictive capability of the 
former (Sun et al., 2016).
CONCLUSIONS
Current evidences from various researchers have indicated 
that poor quality of levofloxacin tablets could be an important 
factor causing resistance of levofloxacin. Clinical efficacy 
of this broad spectrum antibiotic relies on the quality of the 
levofloxacin tablet in term of in vivo release and dissolution 
inside the gastrointestinal tract. As poor performances of 
quality control tests of levofloxacin tablets have been reported 
in developing countries, more PMS to ensure quality of 
levofloxacin tablets are required to prevent therapy failure and 
antibiotic resistance.
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